Sarah B. Noonberg serves as Executive at Protagonist Therapeutics, Inc, where they oversee executive responsibilities. Since joining the company, Sarah B. Noonberg has executed 10 insider transactions totaling $212.6K, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 20, 2026 involved receiving (via award) 12,050 shares valued at $0.
Sarah B. Noonberg currently holds 12,050 shares of Protagonist Therapeutics, Inc (PTGX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sarah B. Noonberg has been a net seller of PTGX stock. They have purchased $0 and sold $212.6K worth of shares.
Sarah B. Noonberg's most recent insider trade was on Feb 20, 2026, when they sold 12,050 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Apr 1, 2024 | MGX | $0 | Award | 57,763 | $N/A | Discretionary |
| Jan 18, 2024 | MRNS | $0 | Award | 4,600 | $N/A | Discretionary |
| May 16, 2023 | MRNS | $0 | Award | 7,200 | $N/A | Discretionary |
| Feb 11, 2021 | PTGX | $92.8K | Sale | 3,700 | $25.09 | Discretionary |
| Feb 11, 2021 | PTGX | $25.8K | Award | 3,700 | $6.98 | Discretionary |
| Feb 10, 2021 | PTGX | $109.3K | Sale | 4,300 | $25.42 | Discretionary |
| Feb 10, 2021 | PTGX | $32.8K | Award | 4,700 | $6.98 | Discretionary |
| Feb 10, 2021 | PTGX | $10.4K | Sale | 400 | $26.04 | Discretionary |